The domestic pharma sector may have been drawing top dollar deals and driving M&As based on opportunities of growth, but stock markets seem to have given it the thumbs down. Contrary to popular perception, over last 12 months, the sector has performed dismally with a majority of stocks giving double-digit negative returns.
